[Masterclass] Improving combination product development with digital continuity

The fast-growing business of combination products has put pharma companies in a unique position to expand their product pipeline, offering up new opportunities for growth and profitability.

By combining drugs with medical devices, pharma organizations are able to deliver considerable value to patients and healthcare providers, such as improved patient compliance and drug delivery. The complexity of combining devices with drugs, however, requires pharma companies to improve business processes around product development and regulatory compliance. Digital technologies, such as digital thread and modelling and simulation will facilitate high quality, fully compliant and fast product discovery, development and commercialization. 

In this one-hour panel masterclass, pharma-experts will dive into the current barriers that hold many pharma companies back from securing the benefits combination products are set to offer.

Panelists will also explore how digital continuity and virtual twins accelerate and improve innovation in the drug-device arena.

Join this masterclass to collaboratively answer:

• Where to start on the drug-device development journey and key activities to avoid.
• What is digital continuity and how it impacts business processes for combination products.
• How to ensure new technology transforms pharma organizations and improves the current way of working.
• If virtual testing is possible.
• How far virtual testing and simulation can be used in the development of combination products.

Sign up today to save your seat.

Presenter:

Dr Barbara Holtz, Expert Business Consultant, Life Sciences at Dassault Systèmes

Barbara Holtz has been working in the life sciences industry for over 20 years, working with companies such as Bayer, GSK and AstraZeneca to help them improve their business processes through digitalization. A PhD physicist by training, Holtz uses her analytical skills to understand what drives the need to digitalize and focuses on manufacturing and sustainability for the pharmaceutical sector, working with companies across Europe.

Khaudeja Bano, Executive Medical Director, Combination Product Safety Head at Amgen

As a global healthcare technology executive with 20 pluse years of experience, Khaudeja Bano drives the development and approval of next-gen healthcare products, including combination products, drug delivery devices, and diagnostic instruments, by directing strategic external outreach, championing product safety, and improving clinical infrastructure. Bano currently works as the Executive Medical Director, Combination Product Safety Head at Amgen, and has previously worked for AbbVie and Abbott Laboratories to build strategies from the ground up for combination product safety. 

Bruce Lau, Senior Manager, R&D Quality - Combination Products at AbbVie

Bruce Lau has launched nine global medical device products for the likes of Stryker, Boston Scientific and Hologic. Previously working at Baxter International, Lau brought on a US$2m manufacturing automation upgrade to increase capacity and was reliable for the annual production of four million disposable infusion pumps with 104 per cent manufacturing efficiency. Currently, Lau is driving data quality and reducing COGS in maximizing net income as the Senior Manager, R&D Quality - Combination Products at AbbVie. 

This masterclass will take place at:

• 3pm CET
• 9am EDT
• 6am PDT
  

Sponsored By: